1. Home
  2. |Insights
  3. |DoD's Own Cyber Monday Deal: Releasing DFARS Cyber Enhancement Guidance

DoD's Own Cyber Monday Deal: Releasing DFARS Cyber Enhancement Guidance

Client Alert | 1 min read | 11.27.18

Just in time for the holidays, the Defense Department published final guidance to the DoD acquisition community that details strategies to enhance existing cybersecurity requirements for Covered Defense Information (CDI) provided by the DFARS Safeguarding Clause 252.204-7012. The DoD’s guidance contains two documents that clarify how DoD will communicate their cybersecurity expectations to contractors, including where those expectations exceed what the DFARS Safeguarding Clause requires:

  • Guidance for Reviewing System Security Plans (SSPs) outlines how the DoD expects to evaluate contractor SSPs, including the preferred method of meeting each NIST security control and the anticipated consequences of not yet having implemented those controls.
  • Guidance for Assessing Compliance and Enhancing Protections provides objectives that requiring activities can tailor to assess contractors’ safeguarding of CDI, including how to incorporate compliance with NIST SP 800-171 and supply chain management as evaluation criteria in solicitations.

Contacts

Insights

Client Alert | 7 min read | 09.14.26

AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development

Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage. ...